Every 424B that Tango Therapeutics Inc (TNGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TNGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNGX filings page.
Tango Therapeutics, Inc. is establishing a new at-the-market equity program to offer up to $400,000,000 of common stock through Leerink Partners as sales agent under its automatic shelf registration. Leerink may sell shares on Nasdaq Global Market, earning up to a 3.0% commission on gross sales.
The company previously had a $100,000,000 ATM under the same sales agreement and has already sold about $64.4 million, or 5,148,151 shares, which offering is now terminated. As of June 30, 2026, 168,380,091 shares were outstanding and net tangible book value was $1.025 billion, or $6.08 per share.
Illustratively, selling $400,000,000 of stock at $27.07 per share would increase net tangible book value to $1.416 billion, or $7.73 per share, implying dilution of $19.34 per share to new investors. Net proceeds are expected to fund working capital, operating expenses, and research and development, including manufacturing and clinical trial costs.
Tango Therapeutics is offering 18,166,667 shares of common stock and pre-funded warrants to purchase 1,833,395 shares. The public offering price is $30.00 per share (pre-funded warrant price $29.999) and the offering is being made pursuant to a shelf registration statement. The underwriters may purchase up to an additional 3,000,009 shares. Net proceeds to the company are estimated at approximately $566.5 million, which the company intends to use for general corporate purposes, R&D, pivotal trial expenses and potential commercialization preparation.
Tango Therapeutics is offering $500,000,000 of its common stock pursuant to a preliminary prospectus supplement dated June 8, 2026. The offering is made under the company’s shelf registration on Form S-3. The prospectus states 144,162,543 shares outstanding as of March 31, 2026, and that net tangible book value was $391.5M, or $2.72 per share as of that date. The underwriters have a 30-day option to purchase up to an additional $75,000,000 of shares. The prospectus describes intended uses of proceeds for general corporate purposes, R&D, pivotal trial expenses and potential commercialization, and states the company expects proceeds plus existing cash to fund operations into 2030. The offering includes customary underwriting arrangements, a 60-day lock-up for certain insiders, and continued availability of an ATM program with up to $35.6M capacity as of June 5, 2026.
Tango Therapeutics (TNGX) launched a primary offering of 21,023,337 shares of common stock and pre-funded warrants to purchase up to 3,226,458 shares, with the warrant shares also covered by this supplement. The offering is priced at $8.66 per share and $8.659 per pre-funded warrant, for a total offering price of $209,999,998, yielding estimated net proceeds of $197,399,805 before expenses.
In a concurrent private placement, Tango agreed to sell 1,732,101 shares at $8.66 per share; those securities are not registered here, and this offering is not conditioned on the PIPE. The company estimates cash, cash equivalents and marketable securities of approximately $152.8 million as of September 30, 2025. Tango intends to use proceeds to advance its pipeline and for general corporate purposes, stating that the combined funds are expected to support operations into 2028. The underwriter expects to deliver the securities on or about October 24, 2025.